BioSpace News Archive

Business

Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced the appointment of Scott Giacobello, CPA, to the role of Chief Financial Officer and Treasurer, effective November 28, 2021.

November 1, 2021
·
6 min read
Biotech Bay

Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) - Nov 01, 2021

Cytokinetics, Incorporated announced that on October 29, 2021 it granted stock options to purchase an aggregate of 68,550 shares of common stock to 8 new employees, whose employment commenced in October 2021, as a material inducement to their employment.

November 1, 2021
·
3 min read
Biotech Bay

Berkeley Lights to Present on Cell Line Development of Complex Molecules and Accelerating Antibody Discovery Against Difficult Targets at 13th Annual PEGS Europe

Berkeley Lights, Inc., a leader in digital cell biology, announced its participation at the 13th Annual PEGS Europe: Protein & Antibody Engineering Summit, being held virtually and in person from November 2-4, 2021, in Barcelona, Spain.

November 1, 2021
·
4 min read
Biotech Beach

Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences - Nov 01, 2021

Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, announced that it will be participating in the following investors conferences during the month of November.

November 1, 2021
·
1 min read
Business

Semler Reports Third Quarter and Year-to-Date 2021 Financial Results

Semler Scientific, Inc., a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, reported financial results for the three and nine months ended September 30, 2021.

November 1, 2021
·
9 min read
Genetown

Compass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market

Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, announced that it has priced an underwritten public offering to sell 35,715,000 shares of common stock at a public offering price of $3.50 per share.

November 1, 2021
·
5 min read